The GLP-1 Duopoly: Is the Market Overlooking Novo Nordisk's Secret Weapon?
A Deep-Dive into the Long-Term Value Proposition of Novo Nordisk vs. Eli Lilly
Key points
The pharmaceutical world is in the throes of a revolution, and its name is GLP-1. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs initially developed for type 2 diabetes, have demonstrated breathtaking efficacy in treating obesity, setting off a market explosion of unprecedented scale. At the heart of this gold rush are two titans: the Danish stalwart Novo Nordisk (NVO) and the American giant Eli Lilly (LLY). Their respective blockbusters—NVO's Ozempic and Wegovy (semaglutide) and LLY's Mounjaro and Zepbound (tirzepatide)—are reshaping medicine, tackling the twin pandemics of diabetes and obesity, and generating staggering profits.
Yet, a fascinating story is unfolding in the stock market. While both companies dominate the GLP-1 space, Eli Lilly has become the undisputed market darling. As of May 2025, LLY boasts a market capitalization dramatically higher than NVO's, a premium awarded for the blistering launch of its obesity drug, Zepbound, and the widespread belief in the superiority of its pipeline.
This report will argue that while the market's enthusiasm for Eli Lilly is understandable, it may be creating a compelling long-term opportunity for discerning investors in Novo Nordisk. The market, fixated on a head-to-head battle for weight-loss percentages, appears to be underappreciating a crucial, strategic advantage NVO has been methodically building for years: a deep and advanced pipeline leveraging its star molecule, semaglutide, across a vast landscape of chronic diseases. This "hidden" value proposition could not only secure NVO's long-term growth but also redefine its flagship drug as a foundational therapy for some of the most prevalent and costly conditions of our time.
The Market Narrative: Why Lilly is Winning the Popularity Contest
To understand the case for Novo Nordisk, we must first appreciate why Eli Lilly's stock has soared. The answer lies in a combination of clinical superiority, masterful commercial execution, and a pipeline that has captured the imagination of investors.
A Clinical Knockout: The narrative shifted decisively in Lilly's favor with the results of the SURMOUNT-5 trial, a head-to-head showdown between LLY's Zepbound and NVO's Wegovy for obesity treatment. The data was unequivocal: Zepbound demonstrated statistically superior weight loss. Patients on Zepbound achieved an average weight reduction of 20.2%, significantly higher than the 13.7% for those on Wegovy. This clinical victory gave Lilly a powerful marketing tool and fueled Zepbound's rapid ascent, capturing over 60% of total U.S. prescriptions in the branded anti-obesity market by the first quarter of 2025.
Growth and Market Share: The sales figures reflect this momentum. In Q1 2025, Eli Lilly's revenue surged 45% year-over-year to $12.73 billion, powered by a combined $6.15 billion from Mounjaro and Zepbound. In contrast, Novo Nordisk's growth, while still impressive at 18% (at constant exchange rates), was slower. Lilly's total GLP-1 sales grew 164% year-over-year in the first quarter, dwarfing the 36% growth for NVO's flagship products. This superior growth trajectory is the primary engine behind LLY's valuation premium.
The Pipeline Buzz: The market is forward-looking, and investors are betting heavily on Lilly's next act. Its pipeline is headlined by two potential game-changers:
Retatrutide: A GIP/GLP-1/Glucagon "tri-agonist" that has shown staggering potential for up to 24.2% weight loss in early-phase trials.
Orforglipron: A once-daily oral GLP-1 pill that promises greater convenience, potentially unlocking a massive patient population averse to injections.
Analysts widely perceive these assets as potentially best-in-class, solidifying Lilly's path to long-term leadership in the obesity market.
The Valuation Disconnect: Paying a Premium for Perfection
The market's bullishness on Eli Lilly is starkly reflected in its valuation metrics. As of May 2025, LLY's market capitalization hovered around $750 billion, more than double Novo Nordisk's ~$300 billion.
This chasm exists despite Novo Nordisk currently leading in several key areas. NVO's combined sales for Ozempic and Wegovy in Q1 2025 were approximately $7.6 billion, out-earning the $6.15 billion from LLY's Mounjaro and Zepbound. Furthermore, NVO's last twelve months free cash flow was a robust $11.5 billion, while LLY's was a mere $4 billion, a figure heavily impacted by massive strategic investments in acquisitions and manufacturing.
The valuation gap is most apparent in the forward price-to-earnings (P/E) multiple. Eli Lilly trades at a rich forward P/E of roughly 33-36x its 2025 earnings estimates. Novo Nordisk, by contrast, trades at a much more conservative ~16-20x multiple, with some analysts citing a forward P/E below 16x. The market is pricing Lilly for near-flawless execution and sustained, explosive growth, while applying a more cautious multiple to Novo Nordisk, reflecting headwinds like competition from compounded drugs and perceived threats to its market share.
The Hidden Value: NVO's Untapped Chronic Disease Empire
Herein lies the core of the investment thesis: the market's focus on the GLP-1 weight-loss race may be causing it to overlook the immense, diversified, and de-risking value of Novo Nordisk's strategy to expand semaglutide's use across a multitude of chronic diseases. NVO has been diligently and strategically investing in large-scale clinical trials to prove its drug's worth far beyond diabetes and obesity, a strategy that is now bearing significant fruit.
This approach is scientifically grounded in the pleiotropic—or multi-faceted—effects of GLP-1 receptor activation, which include anti-inflammatory, cardiovascular, and potential neuroprotective benefits. If semaglutide secures approvals for conditions like chronic kidney disease (CKD), cardiovascular disease, and metabolic liver disease (MASH), it could become a foundational "one-stop-shop" therapy for patients with complex, interconnected conditions. This would create a powerful competitive moat, insulating NVO from competitors whose primary selling point is simply a higher percentage of weight loss.
A Cascade of Clinical Wins:
Novo Nordisk's lead in this area is not speculative; it is backed by a string of late-stage clinical trial successes and regulatory approvals that Eli Lilly has yet to match with its own GLP-1 asset, tirzepatide.
Cardiovascular (CV) Disease: This is NVO's crown jewel. The landmark SELECT trial showed that Wegovy cut the risk of major adverse cardiovascular events (MACE) by a remarkable 20% in obese patients with pre-existing heart disease but without diabetes. This led to a crucial FDA label expansion, making Wegovy the only drug in its class approved to reduce heart attack and stroke risk in this population. This is a massive differentiator that provides a compelling reason for prescription beyond weight loss, especially in the Medicare population. Eli Lilly's equivalent trial for Zepbound, SURMOUNT-MMO, will not have results until 2027.
Chronic Kidney Disease (CKD): In the FLOW trial, Ozempic demonstrated a 24% relative risk reduction in kidney disease progression and death from cardiovascular or kidney causes in patients with type 2 diabetes and CKD. This compelling data led to another FDA label expansion in January 2025, cementing Ozempic's role in protecting a vital organ commonly damaged by diabetes.
Metabolic Dysfunction-Associated Steatohepatitis (MASH): MASH (also known as NASH) is a silent liver disease with no approved therapies until recently, representing a huge unmet need. NVO's ESSENCE trial showed that semaglutide led to MASH resolution in ~63% of patients. The company has already submitted for approval, and the FDA has granted it a priority review, with a decision expected in late 2025. An approval would open up another blockbuster market.
Alzheimer's Disease: In a high-risk, high-reward venture, Novo Nordisk is conducting two large Phase 3 trials, EVOKE and EVOKE+, to see if oral semaglutide can slow cognitive decline in early-stage Alzheimer's. Results are expected in 2025. A positive outcome would be transformative, unlocking a market of immense scale. Notably, Eli Lilly's main Alzheimer's bet is on a different mechanism (donanemab), not its GLP-1 franchise, giving NVO a potential exclusive in this space if semaglutide is successful.
Other Conditions: NVO has also reported positive Phase 3 data for Wegovy in treating knee osteoarthritis (significant pain reduction) and for Ozempic in Peripheral Arterial Disease (improved walking distance).
The Strategic Advantage: Beyond the Scale
This pipeline of chronic disease indications gives Novo Nordisk several powerful long-term advantages that may not be fully reflected in its current stock price:
First-Mover Advantage: NVO is demonstrably ahead of LLY in securing approvals and generating Phase 3 data for its GLP-1 in CKD and broad cardiovascular risk reduction.
The "Halo Effect": A physician treating a single patient with obesity, type 2 diabetes, and chronic kidney disease would have a strong, evidence-based reason to prescribe one drug—semaglutide—that addresses all three conditions. This simplifies treatment and offers compelling health economic benefits for payers.
Physician Familiarity and Trust: Millions of patients have already used Ozempic and Wegovy, establishing a vast safety database and a high degree of physician comfort. This makes it easier for doctors to adopt the drug for new indications, accelerating uptake.
Defensive Moat: As the market becomes crowded with drugs that offer high levels of weight loss, having unique, approved indications for life-threatening chronic diseases provides a durable competitive advantage that is difficult for rivals to replicate quickly.
Long-Term Outlook and Investment Thesis
Eli Lilly is a phenomenal company executing at the highest level. It deserves a premium valuation for its innovation and aggressive growth. However, that premium has become so substantial that it may be pricing in a level of perfection that leaves little room for error.
Novo Nordisk, on the other hand, presents a different picture. The market is currently penalizing it for near-term headwinds like the (now-receding) issue of compounded drugs and for losing the "weight-loss Olympics" in a single head-to-head trial.
The investment thesis is that this narrative is too narrow. It overlooks the immense, tangible value being created in NVO's labs and clinical trials. Over the next two to seven years, as data from the Alzheimer's trials read out and as semaglutide gains further traction as a multi-purpose chronic disease therapy, its revenue streams are set to diversify and expand significantly. Each new indication—from MASH to osteoarthritis—adds another layer to NVO's growth story and solidifies its competitive moat. This progressive realization of "hidden value" could lead to a significant re-rating of Novo Nordisk's stock, narrowing the valuation gap with its chief rival.
From a pure valuation perspective, the argument for Novo Nordisk becomes even more compelling. The company trades at a forward price-to-earnings (P/E) ratio of less than 20x, with some forward estimates placing it closer to 15x. This multiple represents a significant discount not only to its main rival but to the broader market for a company exhibiting such powerful growth and market leadership. When a company of this caliber trades at a P/E and Price-to-Free-Cash-Flow multiple in the mid-teens, it signals a potential mispricing by a market overly focused on short-term sentiment.
This attractive valuation is supported by a fortress-like financial position. Novo Nordisk has a track record of predictable, high-growth earnings, with revenues climbing 26% in 2024 and another 18% in the first quarter of 2025. Its ability to generate cash is immense, as shown by its powerful LTM free cash flow of $11.5 billion. Furthermore, the company maintains a pristine balance sheet with very little debt. This combination of a reasonable price, predictable growth, robust cash generation, and financial stability forms the bedrock of a classic long-term investment case, suggesting that today's price offers a compelling entry point for those willing to look beyond the immediate headlines.
Disclaimer: This commentary is for informational purposes only and does not constitute financial advice. The opinions expressed may not reflect those of Altbridge AI as a firm. Please do your own due diligence or consult a professional before making investment decisions. Markets are volatile and past performance is not indicative of future results.